{"nct_id":"NCT06868277","title":"A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer","status":"RECRUITING","status_verified_date":"2025-09","start_date":"2025-04-10","start_date_type":"ACTUAL","primary_completion_date":"2030-01-17","primary_completion_date_type":"ESTIMATED","completion_date":"2030-12-02","completion_date_type":"ESTIMATED","phases":["PHASE3"],"tickers":["AZN"]}